Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication
Background: Once-daily treatment formulation is associated with better adherence in comparison to more complex medication regimens. The study aimed to detect the extent of adherence to pharmacotherapy in Parkinson disease (PD) patients who take a minimum of three daily doses of drugs, and to identif...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-07-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2019.00799/full |
id |
doaj-acc1f572ea014b36a3390cc5112c38fb |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Igor Straka Michal Minár Matej Škorvánek Milan Grofik Katarína Danterová Ján Benetin Egon Kurča Andrea Gažová Veronika Boleková Veronika Boleková Kathryn A. Wyman-Chick Ján Kyselovič Peter Valkovič Peter Valkovič |
spellingShingle |
Igor Straka Michal Minár Matej Škorvánek Milan Grofik Katarína Danterová Ján Benetin Egon Kurča Andrea Gažová Veronika Boleková Veronika Boleková Kathryn A. Wyman-Chick Ján Kyselovič Peter Valkovič Peter Valkovič Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication Frontiers in Neurology adherence antiparkinson drugs non-motor symptoms Parkinson's disease quality of life |
author_facet |
Igor Straka Michal Minár Matej Škorvánek Milan Grofik Katarína Danterová Ján Benetin Egon Kurča Andrea Gažová Veronika Boleková Veronika Boleková Kathryn A. Wyman-Chick Ján Kyselovič Peter Valkovič Peter Valkovič |
author_sort |
Igor Straka |
title |
Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication |
title_short |
Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication |
title_full |
Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication |
title_fullStr |
Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication |
title_full_unstemmed |
Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication |
title_sort |
adherence to pharmacotherapy in patients with parkinson's disease taking three and more daily doses of medication |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Neurology |
issn |
1664-2295 |
publishDate |
2019-07-01 |
description |
Background: Once-daily treatment formulation is associated with better adherence in comparison to more complex medication regimens. The study aimed to detect the extent of adherence to pharmacotherapy in Parkinson disease (PD) patients who take a minimum of three daily doses of drugs, and to identify factors associated with lower levels of adherence.Methods: The cohort was selected from non-demented PD patients. The 8-Item Morisky Medication Adherence Scale (MMAS-8), 8-Item Parkinson's Disease Questionnaire (PDQ-8), Geriatric Depression Scale (GDS), Non-Motor Symptom Assessment Scale (NMSS), 9-Item Wearing-off Questionnaire (WOQ-9), MDS-UPDRS III (motor examination), and IV (motor complications) scales were used in this study.Results: From a total of 124 subjects, 33.9% reported a high level of adherence, 29.8% reported a medium level of adherence, and 36.3% reported a low level of adherence to their pharmacotherapy. The level of non-adherence correlated with gender, longer disease duration, higher scores of PDQ-8, NMSS, WOQ-9, and MDS-UPDRS IV. Detailed analysis of NMSS demonstrated a correlation between the level of adherence and domains sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, and urinary symptoms. Independent risk factors for non-adherence were excessive daytime sleepiness, anhedonia, and forgetfulness.Conclusion: Non-adherence to more complicated medication regimens is frequent in PD patients and is associated with gender, longer PD duration, poorer quality of life, frequency and severity of non-motor symptoms, and more severe motor and non-motor fluctuations. Non-adherence was predicted by non-motor symptoms including fatigue, mood disturbances, and subjective cognitive complaints. |
topic |
adherence antiparkinson drugs non-motor symptoms Parkinson's disease quality of life |
url |
https://www.frontiersin.org/article/10.3389/fneur.2019.00799/full |
work_keys_str_mv |
AT igorstraka adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication AT michalminar adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication AT matejskorvanek adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication AT milangrofik adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication AT katarinadanterova adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication AT janbenetin adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication AT egonkurca adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication AT andreagazova adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication AT veronikabolekova adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication AT veronikabolekova adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication AT kathrynawymanchick adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication AT jankyselovic adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication AT petervalkovic adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication AT petervalkovic adherencetopharmacotherapyinpatientswithparkinsonsdiseasetakingthreeandmoredailydosesofmedication |
_version_ |
1725978844953837568 |
spelling |
doaj-acc1f572ea014b36a3390cc5112c38fb2020-11-24T21:26:34ZengFrontiers Media S.A.Frontiers in Neurology1664-22952019-07-011010.3389/fneur.2019.00799473505Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of MedicationIgor Straka0Michal Minár1Matej Škorvánek2Milan Grofik3Katarína Danterová4Ján Benetin5Egon Kurča6Andrea Gažová7Veronika Boleková8Veronika Boleková9Kathryn A. Wyman-Chick10Ján Kyselovič11Peter Valkovič12Peter Valkovič13Second Department of Neurology, Comenius University in Bratislava Faculty of Medicine, University Hospital Bratislava, Bratislava, SlovakiaSecond Department of Neurology, Comenius University in Bratislava Faculty of Medicine, University Hospital Bratislava, Bratislava, SlovakiaDepartment of Neurology, Pavol Jozef Safarik University in Kosice Faculty of Medicine, University Hospital of Louis Pasteur, Košice, SlovakiaDepartment of Neurology, Comenius University in Bratislava Jessenius Faculty of Medicine in Martin, University Hospital Martin, Martin, SlovakiaDepartment of Neurology, University Hospital Bratislava, Slovak Medical University, Bratislava, SlovakiaDepartment of Neurology, University Hospital Bratislava, Slovak Medical University, Bratislava, SlovakiaDepartment of Neurology, Comenius University in Bratislava Jessenius Faculty of Medicine in Martin, University Hospital Martin, Martin, SlovakiaComenius University in Bratislava Faculty of Medicine, Institute of Pharmacology and Clinical Pharmacology, Bratislava, SlovakiaSecond Department of Neurology, Comenius University in Bratislava Faculty of Medicine, University Hospital Bratislava, Bratislava, SlovakiaPan-European University Faculty of Psychology, Institute of Clinical Psychology, Bratislava, SlovakiaHealthPartners Neuroscience Center, Saint Paul, MN, United StatesFifth Department of Internal Medicine, Comenius University in Bratislava Faculty of Medicine, University Hospital Bratislava, Bratislava, SlovakiaSecond Department of Neurology, Comenius University in Bratislava Faculty of Medicine, University Hospital Bratislava, Bratislava, SlovakiaCentre of Experimental Medicine, Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Bratislava, SlovakiaBackground: Once-daily treatment formulation is associated with better adherence in comparison to more complex medication regimens. The study aimed to detect the extent of adherence to pharmacotherapy in Parkinson disease (PD) patients who take a minimum of three daily doses of drugs, and to identify factors associated with lower levels of adherence.Methods: The cohort was selected from non-demented PD patients. The 8-Item Morisky Medication Adherence Scale (MMAS-8), 8-Item Parkinson's Disease Questionnaire (PDQ-8), Geriatric Depression Scale (GDS), Non-Motor Symptom Assessment Scale (NMSS), 9-Item Wearing-off Questionnaire (WOQ-9), MDS-UPDRS III (motor examination), and IV (motor complications) scales were used in this study.Results: From a total of 124 subjects, 33.9% reported a high level of adherence, 29.8% reported a medium level of adherence, and 36.3% reported a low level of adherence to their pharmacotherapy. The level of non-adherence correlated with gender, longer disease duration, higher scores of PDQ-8, NMSS, WOQ-9, and MDS-UPDRS IV. Detailed analysis of NMSS demonstrated a correlation between the level of adherence and domains sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, and urinary symptoms. Independent risk factors for non-adherence were excessive daytime sleepiness, anhedonia, and forgetfulness.Conclusion: Non-adherence to more complicated medication regimens is frequent in PD patients and is associated with gender, longer PD duration, poorer quality of life, frequency and severity of non-motor symptoms, and more severe motor and non-motor fluctuations. Non-adherence was predicted by non-motor symptoms including fatigue, mood disturbances, and subjective cognitive complaints.https://www.frontiersin.org/article/10.3389/fneur.2019.00799/fulladherenceantiparkinson drugsnon-motor symptomsParkinson's diseasequality of life |